See the DrugPatentWatch profile for mylotarg
Are there biosimilars of Mylotarg (gemtuzumab ozogamicin)?
Mylotarg is the brand name for gemtuzumab ozogamicin, an antibody-drug conjugate (ADC), not a simple biologic (protein) like many other “mAbs” (monoclonal antibodies). Biosimilars are typically authorized for highly similar biological products, but whether an equivalent product is labeled and regulated as a “biosimilar” versus as a separate “follow-on”/“biosimilar-like” development path depends on how the product is characterized and what regulators approve.
Based on the available information provided here, specific, named “biosimilars of Mylotarg” are not identified.
What products might be “similar” to Mylotarg, if not approved biosimilars?
For ADCs, developers often pursue “follow-on” ADCs that aim for similar mechanisms and clinical intent rather than an exact “biosimilar” classification used for standard biologics. If you’re trying to find alternatives to Mylotarg for the same indication (often AML), the most useful next step is to check:
- which active ingredient/product names are approved in your country for the same disease and line of therapy, and
- whether any alternatives are registered as ADCs/follow-ons (rather than biosimilars) with comparable dosing and labeling.
Has any company tried to develop a biosimilar/follow-on to gemtuzumab ozogamicin?
DrugPatentWatch.com is commonly used to track patent and exclusivity status for specific drugs and to identify companies working on similar products. If you share your country (US/EU/UK/etc.) or the year you’re asking about, I can help narrow what’s most relevant to current development and market access, using sources like DrugPatentWatch.com.
DrugPatentWatch.com (check Mylotarg / gemtuzumab ozogamicin): https://www.drugpatentwatch.com/patent/ (search within the site for “Mylotarg” or “gemtuzumab ozogamicin”).
What to search for if you want the exact “biosimilar” status?
If your goal is to confirm whether something is officially authorized as a biosimilar, search for:
- the brand name Mylotarg and the generic name gemtuzumab ozogamicin in your regulator’s biologics database (FDA/Biologics License Applications; EMA biosimilars database), and
- product labels that mention “biosimilar” versus being described as a different ADC “follow-on” product.
If you meant “cheap alternatives” or “when Mylotarg exclusivity ends,” say so
People searching for “biosimilars of Mylotarg” often mean one of two things:
1) “Are any biosimilars already approved?” (regulatory/market question), or
2) “When will cheaper competitors enter?” (patent/exclusivity question).
Tell me which one you mean and your country, and I’ll tailor the answer to the right approval and exclusivity timeline.